People: Clovis Oncology Inc (CLVS.OQ)
Dr. Gillian C. Ivers-Read is Executive Vice President - Technical Operations, Chief Regulatory Officer of the Company. Ms. Ivers-Read served as Executive Vice President, Development Operations at Pharmion Corporation (acquired in 2008), beginning in 2002. From 1996 to 2001, Ms. Ivers-Read held various regulatory positions with Hoechst Marion Roussel and its successor, Aventis Pharmaceuticals, Inc., where she most recently held the position of Vice President, Global Regulatory Affairs. From 1994 to 1996, Ms. Ivers-Read was Vice President, Development and Regulatory Affairs for Argus Pharmaceuticals, and from 1984 to 1994, she served as a regulatory affairs director for Marion Merrell Dow. Ms. Ivers-Read received a B.Sc. in pharmacology from University College London.
|Total Annual Compensation, USD||661,219|
|Restricted Stock Award, USD||683,100|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||1,039,560|
|Fiscal Year Total, USD||2,383,880|